Inogen, Inc. (INGN)

NasdaqGS • Currently down 0.74 (-10.93%) in today's trading session

2 members of Congress have disclosed 14 trades in Inogen, Inc. (INGN) via STOCK Act filings. The most recent disclosure was a sale by Paul Mitchell on 3 June 2020. The most active traders have been Paul Mitchell (12) and Lamar Smith (2). Aggregate disclosed activity totals roughly $1.1M in purchases and $1.3M in sales (midpoint estimates from bracketed disclosure amounts).

Inogen, Inc. is currently trading at $6.03, positioned at 38% of its 52-week range ($5.04 – $7.67).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$6.03
24h Change
-0.74 (-10.93%)
52 Week Range
$5.04–$7.67
View on NASDAQ

Inogen, Inc. Price History and Technical Analysis

Congressional Trading Activity for INGN

Select to highlight on chart
5 transactions
Compliance: 7%
Paul Mitchell3 Jun 202019 Jan 2021SaleStock$250,001 - $500,000N/A
Paul Mitchell3 Jun 202019 Jan 2021SaleStock$250,001 - $500,000N/A
Paul Mitchell2 Jun 202019 Jan 2021SaleStock$100,001 - $250,000N/A
Paul Mitchell2 Jun 202019 Jan 2021SaleStock$100,001 - $250,000N/A
Paul Mitchell1 Jun 202019 Jan 2021SaleStock$50,001 - $100,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$160.03M

Volume

975.01K

Beta

1.50

P/E Ratio

-6.63

Fundamentals

EPS

$-0.91

Div. Yield

-

Open

$5.45

Day Range

$5.05 – $6.35

Company Information

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ · USD
Country
US
CEO
Kevin R. Smith
IPO Date
2014-02-14

Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persis...

Earnings

Next Report

Q4 2026

25 Feb

EPS Est.

$-0.17

Rev. Est.

$84M

Days Until

108

Recent Quarters

Q3 20265 Nov
EPS$-0.56
Miss 293.5%
Q2 20266 Aug
EPS$-0.14
Beat 8.7%
Q1 20267 May
EPS$-0.30
Miss 25.0%
Q4 202524 Feb
EPS$-0.26
Beat 27.8%
Q3 20255 Nov
EPS$-0.20
Beat 9.1%
Q2 20257 Aug
EPS$-0.15
Beat 31.8%
Q1 20257 May
EPS$-0.25
Beat 51.9%
Q4 202425 Feb
EPS$-0.41
Beat 26.8%
Q3 20247 Nov
EPS$-0.25
Beat 49.0%
Q2 20246 Aug
EPS$-0.24
Beat 56.4%
Q1 20247 May
EPS$-0.62
Beat 18.4%
Q4 202327 Feb
EPS$-1.14
Miss 83.9%
Q3 20237 Nov
EPS$-1.97
Miss 245.6%
Q2 20237 Aug
EPS$-0.42
Beat 28.8%
Q1 20234 May
EPS$-0.88
Miss 14.3%
Q4 202223 Feb
EPS$-0.57
Beat 5.0%
Q3 20222 Nov
EPS$-0.42
Miss 2.4%
Q2 20224 Aug
EPS$-0.15
Beat 62.5%
Q1 20225 May
EPS$-0.62
Miss 29.2%
Q4 202124 Feb
EPS$-1.01
Miss 38.4%
Q3 20214 Nov
EPS$0.53
Beat 303.9%
Q2 20214 Aug
EPS$0.22
Beat 300.0%
Q1 20214 May
EPS$-0.03
Beat 88.9%
Q4 202024 Feb
EPS$-0.23
Beat 11.5%
Q3 20204 Nov
EPS$-0.08
Miss 290.2%
Q2 20204 Aug
EPS$0.12
Beat 250.0%
Q1 20205 May
EPS$-0.07
Beat 36.4%
Q4 201925 Feb
EPS$0.07
Miss 36.4%
Q3 20195 Nov
EPS$0.31
Beat 34.8%
Q2 20197 Aug
EPS$0.45
Miss 8.2%
Q1 20197 May
EPS$0.24
Miss 20.0%
Q4 201826 Feb
EPS$0.44
Beat 76.0%
Q3 20186 Nov
EPS$0.73
Beat 40.4%
Q2 20187 Aug
EPS$0.65
Beat 47.7%
Q1 201830 Apr
EPS$0.48
Beat 65.5%
Q4 201727 Feb
EPS$0.31
Beat 47.6%
Q3 20177 Nov
EPS$0.33
Beat 13.8%
Q2 20173 Aug
EPS$0.38
Beat 35.7%
Q1 20179 May
EPS$0.27
Beat 92.9%
Q4 201628 Feb
EPS$0.25
Beat 127.3%
Q3 20163 Nov
EPS$0.16
Beat 23.1%
Q2 20164 Aug
EPS$0.25
Beat 31.6%
Q1 20169 May
EPS$0.11
Miss 8.3%
Q4 201514 Mar
EPS$0.14
Beat 100.0%
Q3 201510 Nov
EPS$0.13
Beat 0.0%
Q2 201511 Aug
EPS$0.17
Beat 21.4%
Q1 201512 May
EPS$0.08
Beat 0.0%
Q1 201527 Apr
EPS$0.07
Q3 201411 Nov
EPS$0.11
Beat 83.3%
Q2 201412 Aug
EPS$0.11
Beat 57.1%
Q1 201413 May
EPS$0.05
Beat 33.3%
Q4 201327 Mar
EPS$-0.08
Miss 42.9%
Q2 201330 Sept
EPS$0.05
Q1 201330 Jun
EPS$0.12
Q4 201231 Mar
EPS$0.04
Q3 201231 Dec
EPS$0.01
Q2 201230 Sept
EPS$-0.08

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

WST

West Pharmaceutical Services, Inc.

47
$399.81+7.33 (+1.87%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

UNH

UnitedHealth Group Incorporated

47
$394.15-1.57 (-0.40%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

GOOGL

Alphabet Inc.

17
$284.78+2.21 (+0.78%)
Communication Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about INGN

Which members of Congress have traded INGN?
2 members of Congress have disclosed 14 trades in Inogen, Inc. (INGN) under the STOCK Act. The most active traders are Paul Mitchell and Lamar Smith.
When was INGN most recently disclosed by Congress?
The most recent INGN disclosure was a sale by Paul Mitchell on 3 June 2020.
What is the total disclosed congressional trading volume for INGN?
Members of Congress have disclosed approximately $1.1M in INGN purchases and $1.3M in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in INGN?
This INGN page updates as soon as new STOCK Act disclosures are filed for Inogen, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.